GlassScriptPhysician profile
Terry L Tucker
NPI 1033100060
$5,778.97
in general payments reported to CMS, 2019-2025
24 companies · $763 in 2025
The $763 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,674 · 2020: $436 · 2021: $938 · 2022: $715 · 2023: $578 · 2024: $675 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Entertainment: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.44 |
| Entertainment | $297.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $815.37 | 2019-2025 | Tryptyr, Precision 1 |
| Coopervision INC. | $704.77 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Optos, INC. | $549.31 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $491.58 | 2022-2025 | Infuse Multifocal, Infuse |
| Johnson & Johnson Vision Care, INC. | $427.36 | 2019-2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $365.19 | 2019-2021 | |
| Biotissue Holdings INC. | $328.28 | 2024-2025 | |
| Maculogix, INC. | $323.80 | 2019-2020 | |
| Dompe US, INC. | $246.41 | 2021-2024 | Oxervate |
| Optovue, INC. | $243.60 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $171.10 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $125.76 | 2021 | |
| Glaukos Corporation | $124.47 | 2025 | Idosetr |
| Regeneron Healthcare Solutions, INC. | $111.40 | 2019 | |
| Sight Sciences, INC. | $100.37 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $99.93 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $98.08 | 2022-2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $91.51 | 2022 | |
| Lkc Technologies, INC. | $88.46 | 2025 | |
| Amgen INC. | $84.48 | 2024 | Tepezza |
| Konan Medical USA, INC. | $78.81 | 2019 | |
| Shire North American Group INC | $65.96 | 2019 | |
| Visionix USA, INC | $35.18 | 2022 | |
| Abb Con-Cise Optical Group LLC | $7.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.